Avastin For Lung Cancer Will Be Free To Patients Who Beat The Average
Executive Summary
Under a Genentech program that caps expenditures for Avastin, the oncologic will be free of charge to patients who continue using the therapy beyond the median duration of treatment for lung cancer
You may also be interested in...
Post-Market Trials Could Broaden Label For Allos' Newly Approved Folotyn
Two of the four post-market studies Allos is required to conduct as part of Folotyn's Sept. 24 accelerated approval could broaden the label of the oncologic, newly cleared for treatment of relapsed or refractory peripheral T-cell lymphoma
Post-Market Trials Could Broaden Label For Allos' Newly Approved Folotyn
Two of the four post-market studies Allos is required to conduct as part of Folotyn's Sept. 24 accelerated approval could broaden the label of the oncologic, newly cleared for treatment of relapsed or refractory peripheral T-cell lymphoma
Post-Market Requirements Could Broaden Label For Allos' Newly Approved PTCL Drug Folotyn
Allos gains its first U.S. indication with the accelerated approval of Folotyn (pralatrexate) in peripheral T-cell lymphoma.